We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

LifeSign LLC

LifeSign is a medical diagnostic company delivering rapid point of care testing solutions for caregivers in critical ... read more Featured Products: More products

Download Mobile App





Carolina Liquid Chemistries Offers FDA Emergency Use Authorized POC COVID-19/Flu A&B Combo Test

By LabMedica International staff writers
Posted on 24 Mar 2021
Carolina Liquid Chemistries, Corp. More...
(CLC, Greensboro, NC, USA) has made yet another addition to its Point-of-Care product line by offering the Emergency Use Authorized Status COVID-19/Flu A&B Combo Test from LifeSign LLC (Skillman, NJ, USA).

The Status COVID-19/Flu A&B Combo Test is a lateral flow immunoassay intended for the in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV-2, Influenza A, and Influenza B directly from nasopharyngeal swab specimens obtained from individuals, who are suspected of respiratory viral infection consistent with COVID-19 and/or influenza by their healthcare provider, within the first five days of onset of symptoms.

To respond effectively to the COVID-19 outbreak, rapid detection of cases, stringent performance assessment, and increase in the current diagnostic capacity are still urgently needed. As the early symptoms of COVID-19 are similar to those of seasonal Influenza A or B, a rapid detection test to specifically diagnose symptomatic patients is urgently needed. The Status COVID-19/Flu A&B Combo Test is intended to aid in the rapid differential diagnosis of Influenza A, B, and SARS-CoV-2 viral infection.

"The Status COVID-19/Flu A&B Combo Test is a vital combination test for the current market. Anytime we can make testing easier, faster, less expensive, and more efficient for the patient and provider, we know we are doing our job," said Phil Shugart, CEO of Carolina Liquid Chemistries Corp.

Related Links:
Carolina Liquid Chemistries, Corp.
LifeSign LLC



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Candida Glabrata Test
ELIchrom Glabrata
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.